Background: We report here the prognostic value of ploidy and digital tumour-stromal morphometric analyses using material from 2624 patients with early stage colorectal cancer (CRC).
Introduction
Biomarkers are being used increasingly to select populations of cancer patients who are likely to benefit most from treatment and avoid life threatening toxicity [1, 2] . However, the dominant management decision in the adjuvant setting is whether any treatment should be offered at all, given its relatively marginal benefits [3] . For example, a 6-month postoperative course of 5-fluorouracil and folinic acid or capecitabine improves overall survival (OS) by around 3%-5% for patients with stage II or IIIA colorectal cancer. The vast majority (75%-80%) of these patients will be cured by surgery alone; 15%-20% will recur despite adjuvant chemotherapy; there is likely to be a chemotherapy associated death rate of 0.5%-1%; and 20% of patients will suffer significant side effects [4] [5] [6] [7] . The risk-benefit ratio is therefore marginal, but would be positively skewed if it were possible to define a subgroup at higher risk of recurrence and cancer specific death.
Although clinically validated prognostic biomarkers would facilitate adjuvant therapeutic decisions, until recently, none have been sufficiently robust for routine clinical application. We recently reaffirmed the prognostic value of DNA mismatch repair (MMR) status in 1913 patients enrolled in the QUASAR trial [8] and identified those 12%-15% of MMR-deficient, stage II patients at a reduced risk of recurrence and in whom adjuvant therapy is not indicated [9, 10] . Similarly, a clinical argument has been presented for use of an RNA signature-based risk score to stratify T3 N0, MMR-proficient colorectal tumours [11] . A number of studies have shown that manually assessed stroma fraction is a prognostic marker in colorectal cancer (CRC) [12] [13] [14] [15] . Further subdivision was investigated by Angell and Galon [16] , who explored the prognostic impact of immune infiltrates.
The aim of the present study was to undertake morphometric and molecular analysis of a series of primary CRC specimens collected retrospectively from patients entered into a trial (QUASAR) of adjuvant therapy and two large observational cohorts to validate the combination of ploidy and stromal fraction as a potentially clinically useful prognostic marker.
Methods

QUASAR 2 study
A total of 1952 patients, who had undergone surgery for stage III/high risk stage II CRC, were randomly assigned to receive capecitabine alone, comprising a 3-week cycle of 1250 mg/m 2 twice daily for 14 days followed by a 7 days break for a total of eight cycles, or the same in combination with bevacizumab, 7.5 mg/kg intravenous infusion over 90 minutes on day 1 of each 3-week cycle. The primary end point was 3-year disease-free survival (DFS) with OS a secondary end point.
The study was undertaken in accordance with the protocol, good clinical practice, the EU Directive 2001/20/EC and 2005/28/EC, and the Declaration of Helsinki, and was approved by West Midlands Research Ethics Committee, United Kingdom (REC reference: 04/MRE/11/18). An independent data safety monitoring committee carried out annual safety reviews. This trial is registered, number ISRCTN 4513315.
Gloucester cohort
The Gloucester Colorectal Cancer Study was carried out between 1988 and 1996 and recruited 1050 patients. A small proportion of the patients (7% among stage II and 15% among stage III) received adjuvant therapy. The prognostic impact of peritoneal involvement has been evaluated in the colonic and rectal cancers in this cohort previously [17, 18] . The Gloucestershire Local Research Ethics Committee, under reference 01/ 21G, approved the study.
Oslo University Hospital-Aker cohort
This cohort is a consecutive series of 578 stages I-III colorectal cancer patients treated at Oslo University Hospital-Aker, Norway, in the period 1993-2003. A minority of the patients received adjuvant therapy (1% among stage II and 30% among stage III patients). The prognostic impact of DNA ploidy and microsatellite instability (MSI) status has been reported in the same patient cohort previously [19, 20] 
Tumour sampling
For analyses, the pathologist selected one tumour block deemed representative from each patient, and annotated the whole epithelial tumour region. Hence, no systematic selection was carried out.
DNA ploidy analysis
DNA ploidy analysis by image cytometry was carried out as previously reported [21] .
Tumour-stroma fraction
The tumour-stroma fraction was measured on the histological images using developed proprietary software tools and analysis methods as described in supplementary methods, available at Annals of Oncology online. The method for automatically segmenting tumour-stroma in HE-stained tissue sections (Supplementary Figure S1 , available at Annals of Oncology) was developed in a separate dataset where a pathologist evaluated the segmentation results during development. The cutoff value for low and high stroma was taken from a previous study where stroma fraction was manually assessed [12] .
Statistical analysis
All pathological and laboratory assessments were undertaken blind to the patients' treatment allocation and clinical outcomes.
Five-year cancer-specific survival (CSS) was the end point common to all datasets and was used for the individual and pooled analyses. For QUASAR 2, survival time was calculated from date of randomisation. An event was defined as cancer death within 5 years. Observations were censored at death from other causes or at 5 years after randomisation, whichever occurred first. For the Gloucester and Aker datasets, survival time was calculated from surgery date.
For assessment of the prognostic value of variables, cancer-specific mortality rates over the follow-up period of 5 years were analysed. Only variables that were significant in univariate analyses in the pooled dataset were included in the multivariate analysis, with the exception of age. Estimated survival functions were compared using the Mantel-Cox log-rank test in univariate analysis of categorical variables and the Wald chi-squared test in multivariate analysis. Analyses were carried out using R version 3.1.3.
Results
Patient demography
The majority of patients had colon cancer (75%), median age of 68 years, a male preponderance (55% versus 45%), a majority of stage III patients (53% versus 39% stage II and 7% stage I), with stage II subjects having a higher proportion of MSI (18% versus 11%, Table 1 ). Stages II and III had more high stroma tumours compared with stage I (13% versus 7%, supplementary Tables S1A-C, available at Annals of Oncology online). All patients in the QUASAR 2 cohort received chemotherapy (capecitabine 6 bevacizumab), whereas 1% of the Aker and 7% of the Gloucester stage II patients were treated with chemotherapy.
Univariate prognostic factors for CSS
Univariate analyses of the individual datasets are summarised in supplementary Tables S1A-C, available at Annals of Oncology online.
In the pooled dataset, the combination of ploidy and stroma was statistically significant in stage II tumours (P < 0.001, 17 (2) 14 (1) 27 (5) 58 (2) pT2 70 (7) 70 (7) 103 (18) 243 (9) The combination of pathological T-stage and degree of tumour differentiation was not prognostic in stage II disease (Figure 2A) QUASAR 2 patients receiving bevacizumab did not have a significantly different prognosis than those that received capecitabine alone when stratifying for stroma content and stage, indicating that patients with a high stroma content do not benefit from VEGF inhibition (supplementary Tables S4A and B, available at Annals of Oncology online).
Multivariate analyses of prognostic factors for CSS
Multivariate analyses of the individual datasets are summarised in supplementary Tables S2A-F, S3A-D and S5A-C, available at Annals of Oncology online.
The pooled dataset comprising QUASAR 2, Gloucester and Aker populations are summarised in Tables 2 and 3 . In multivariate modelling, the dominant contributory factors for stage II disease were the combination of ploidy and stroma [P < 0. 
Discussion
Like most epithelial tumours, CRCs are composed of two interdependent cellular compartments: malignant epithelium and tumour stroma. Tumour stroma (consisting of extracellular matrix admixed with fibroblasts, myofibroblasts, endothelial cells and inflammatory and immune infiltrative cells) is considered to make a critical contribution to tumour biology in terms of survival, growth, invasion and metastatic potential.
Recently, tumour-stromal measurement utilising visual estimation has been applied to tissue sections from 710 patients enrolled in the VICTOR trial, suggesting that tumours comprising more than 50% stroma have significantly poorer prognosis [12] . The explanation for the effect described here is currently unknown, but there are data to suggest that there may be enhanced pro-invasive signalling by intra-stromal myofibroblasts or growth factor/cytokine production by cancer-associated fibroblasts inducing enhanced angiogenesis, increased tumour growth and invasion, possibly through induction of a mesenchymal stem cell phenotype. Guinney et al. [22] used gene expression profiles to define several subtypes of colorectal cancer, one of which, CMS4, showed significant upregulation of genes implicated in epithelial-to-mesenchymal transition and of signatures compatible with stromal infiltration. More recently Isella et al. [23] have shown that the distinctive transcriptional and clinical features of this subtype can be ascribed to its particularly abundant stromal component, consistent with findings in the current study. Angell and Galon [16] have explored the prognostic impact of immune infiltrates. Using digital quantification of CD3 and CD8 lymphocytes following immunohistochemical staining, they suggest that a low immune infiltrate score is associated with a higher relapse rate. Recently, Mlecnik et al. demonstrated the presence of functional mutation-specific cytotoxic T cells and the superiority of immunoscore over MSI in predicting survival, as is the case with the ploidy/stroma assay [24] .
The association between ploidy and poor prognosis is well documented (reviewed in [25] ). Current opinion is that damage to the cellular apparatus of mitosis within epithelial tumours at an early stage can produce cells with chromosomal instability and that these genetically unstable cells drive tumorigenesis by producing progeny with diverse (uncharacterised) genetic alterations conferring survival advantages.
Individually, mutations in TP53, PIK3CA and KRAS are very weak prognostic markers. BRAF, which is prognostic in advanced CRC, is much less so for the primary tumour [8] . Most of these studies have suffered from small sample size, poorly curated tissue banks, inadequate validation on independent datasets and a lack of assay quality control. Morphometric analyses of ploidy and stroma ( Figure 1A ) has provided a technically simple prognostic stratifier for stage II CRC which is likely to be clinically useful. By defining a substantial proportion (34%) of patients with good prognosis (90% 5-year CSS), it will inform discussion with the patient as to the absolute benefits of adjuvant chemotherapy. The HR, separating relatively good from relatively poor prognosis [HR 2.95 (95% CI: 1.73-5.03, P < 0.001] for the ploidy-stromal classifier is superior to the HR generated for stage II colon cancer patients by the RNA signature [11] Oncotype Dx Colon TM (HR ¼ 1.47, P ¼ 0.046), although no direct comparison of the two tests has been made. For patients with high stroma that undergo adjuvant therapy, reports indicate that this group of patients have shorter survival and thus that further substratification is required [15] . Although digital pathology is widely available, the ploidy element of the assay needs to be established in accredited central laboratories, which offer the most practical, initial means of delivering the assay. This combined biomarker was not prognostic for stage III CRC, where the clinical default is to offer patients combination adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin. As shown in Figure 2C , it might be possible to challenge this paradigm and consider single agent chemotherapy for the low-risk group, particularly in elderly patients.
Although there is significant international variation in clinical practice, in the UK, around 50% of stage II colon cancer patients receive adjuvant chemotherapy, a proportion of which is administered in combination, overtreating the general population of patients so that a small minority might benefit. The use of this new prognostic biomarker will identify approximately 34% of stage II patients with a prognosis similar to stage I patients who might therefore avoid adjuvant treatment, 55% of intermediate prognosis who might benefit from adjuvant fluoropyrimidine monotherapy and 11% with a bad prognosis of whom the patient and clinician might consider that combination therapy with oxaliplatin would be merited, in patients under 70 years of age. 
